September 13, 2016: ACTTION Receives Second 5-Year Cooperative Agreement from FDA

ACTTION is very pleased to announce that it has been awarded a second 5 years of funding from the FDA. The award is for up to a maximum of $4,000,000 to support ACTTION’s ongoing and planned efforts to expedite the discovery and development of improved analgesic, anesthetic, addiction, and peripheral neuropathy treatments for the benefit of the public health.